Delaware
|
000-19364
|
62-1117144
|
|||||
(State or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|||||
701 Cool Springs Boulevard
Franklin, Tennessee
|
37067
|
||||||
(Address of principal executive offices)
|
(Zip Code)
|
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
(d) Exhibits:
|
||
Exhibit 99.1
|
Press Release.
|
|
HEALTHWAYS, INC.
|
||
By:
|
/s/ Alfred Lumsdaine
|
|
Alfred Lumsdaine
|
||
Chief Financial Officer
|
Exhibit 99.1
|
Press Release dated February 15, 2012
|
3 Months Ended
December 31,
|
12 Months Ended
December 31,
|
|||||||||||||||
2011 (1)
|
2010
|
2011 (1)
|
2010
|
|||||||||||||
Domestic, excluding restructuring and impairment charges, earn-out adjustment and investment gain, and CMS settlement
|
$
|
0.31
|
|
0.28
|
$ | 0.98 | $ | 1.14 | ||||||||
International, excluding restructuring charges
|
(0.04
|
) |
(0.03
|
) | (0.13 | ) | (0.03 | ) | ||||||||
Adjusted net income per diluted share
|
|
0.27
|
|
0.25
|
0.85 | 1.11 | ||||||||||
Restructuring charges(2) | (0.17 | ) | (0.20 | ) | (0.16 | ) | (0.20 | ) | ||||||||
Impairment charges(2) | (5.43 | ) | - | (5.36 | ) | - | ||||||||||
Earn-out adjustment and investment gain | - | 0.03 | - | 0.07 | ||||||||||||
CMS settlement | - | 0.37 | - | 0.37 | ||||||||||||
Net income (loss) per diluted share(3) | $ | (5.32 | ) | $ | 0.45 | $ | (4.68 | ) | $ | 1.36 |
(1)
|
The assumed exercise of stock-based compensation awards for the three and twelve months ended December 31, 2011 was not considered because the impact would be anti-dilutive.
|
(2)
|
Per-share results differ for the three and twelve months ended December 31, 2011 due to different weighted average outstanding shares and equivalents for each period.
|
(3)
|
Figures may not add due to rounding.
|
1)
|
Health plan preparation for the implementation of state health insurance exchanges, which is projected to cause significant disruption of their individual and small group fully insured business;
|
2)
|
Change from a volume-based to a value-based payment system and the associated shift of financial risk and responsibility for cost and quality from health plans to providers;
|
3)
|
Increasing payer requests for a comprehensive, integrated solution that addresses longitudinal health risk and care needs for total populations;
|
4)
|
Global adoption of population health management by both foreign government and foreign private sector health organizations; and
|
5)
|
Recognition by large employers of the expanded value of improved well-being to reduce medical cost and improve individual and company productivity and performance.
|
Twelve Months
|
|||||||||
Ending | Ended | ||||||||
Dec. 31, 2012
(Guidance)
|
Dec. 31, 2011
(Actual)
|
||||||||
Domestic
|
$
|
638.0 - 670.0
|
$
|
666.7
|
|||||
International
|
27.0 - 35.0
|
22.1
|
|||||||
Revenues
|
$
|
665.0 - 705.0
|
$
|
688.8
|
Twelve Months
|
|||||||||
Ending | Ended | ||||||||
Dec. 31, 2012
(Guidance)
|
Dec. 31, 2011
(Actual) (1)
|
||||||||
Domestic, excluding restructuring and impairment charges
|
$
|
0.42 - 0.50
|
$
|
0.98
|
|||||
International, excluding restructuring charges
|
0.00 - 0.04
|
(0.13
|
) | ||||||
Adjusted net income per diluted share
|
|
0.42 - 0.54
|
|
0.85
|
|||||
Restructuring charges | - | (0.16 | ) | ||||||
Impairment charges | - | (5.36 | ) | ||||||
Net income (loss) per diluted share(2) | $ | 0.42 - 0.54 | $ | (4.68 | ) |
(1)
|
The assumed exercise of stock-based compensation awards for the three and twelve months ended December 31, 2011 was not considered because the impact would be anti-dilutive.
|
·
|
the Company’s ability to sign and implement new contracts;
|
·
|
the Company’s ability to accurately forecast the costs required to successfully implement new contracts;
|
·
|
the Company’s ability to anticipate change and respond to emerging trends in the domestic and international markets for healthcare and the impact of the same on demand for the Company’s services;
|
·
|
the Company’s ability to renew and/or maintain contracts with its customers under existing terms or restructure these contracts on terms that would not have a material negative impact on the Company’s results of operations;
|
·
|
the Company’s ability to accurately forecast the Company’s revenues, margins, earnings and net income, as well as any potential charges that the Company may incur as a result of changes in its business;
|
·
|
the Company’s ability to accurately estimate the financial impact of restructuring actions and the impairment of goodwill;
|
·
|
the Company’s ability to accurately forecast performance and the timing of revenue recognition under the terms of our customer contracts ahead of data collection and reconciliation;
|
·
|
the Company’s ability to accurately forecast enrollment and participation rates in services and programs offered within the Company’s contracts;
|
·
|
the Company’s ability to accurately forecast the costs necessary to establish a presence in international markets;
|
·
|
the risks associated with foreign currency exchange rate fluctuations;
|
·
|
the ability of the Company’s customers to provide timely and accurate data that is essential to the operation and measurement of the Company’s performance;
|
·
|
the Company’s ability to achieve the contractually required cost savings and clinical outcomes improvements and reach mutual agreement with customers with respect to cost savings, or to achieve such savings and improvements within the time frames it contemplates;
|
·
|
the risks associated with changes in macroeconomic conditions;
|
·
|
the Company’s ability to implement its new integrated data and technology solutions platform within the required time frame and expected cost estimates and to develop and enhance this platform and/or other technologies to meet evolving customer and market needs;
|
·
|
the Company’s ability to accurately forecast the costs necessary to integrate new or acquired businesses, services (including outsourced services) or technologies into the Company’s business;
|
·
|
the impact of litigation involving the Company and/or its subsidiaries;
|
·
|
the impact of future state, federal and international legislation and regulations applicable to the Company’s business, including the Patient Protection and Affordable Care Act, on the Company’s ability to deliver its services and on the financial health of the Company’s customers and their willingness to purchase the Company’s services; and
|
·
|
other risks detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010, and other filings with the Securities and Exchange Commission.
|
Three Months Ended
|
Twelve Months Ended
|
||||||||||||||||
December 31,
|
December 31,
|
||||||||||||||||
2011
|
2010
|
2011
|
2010
|
||||||||||||||
Revenues
|
$
|
179,995
|
$
|
195,324
|
$
|
688,765
|
$
|
720,333
|
|||||||||
Cost of services (exclusive of depreciation and amortization of $9,281, $9,733, $36,248, and $39,203, respectively, included below)
|
133,211
|
123,174
|
510,724
|
493,713
|
|||||||||||||
Selling, general & administrative expenses
|
15,120
|
19,473
|
64,843
|
72,830
|
|||||||||||||
Depreciation and amortization
|
12,644
|
13,090
|
49,988
|
52,756
|
|||||||||||||
Impairment loss
|
183,288
|
—
|
183,288
|
—
|
|||||||||||||
Restructuring and related charges
|
9,036
|
10,258
|
9,036
|
10,258
|
|||||||||||||
Operating income (loss)
|
(173,304
|
)
|
29,329
|
(129,114
|
)
|
90,776
|
|||||||||||
Gain on sale of investment
|
—
|
—
|
—
|
(1,163
|
)
|
||||||||||||
Interest expense
|
3,384
|
3,642
|
13,193
|
14,164
|
|||||||||||||
Income (loss) before income taxes
|
(176,688
|
)
|
25,687
|
(142,307
|
)
|
77,775
|
|||||||||||
Income tax expense
|
382
|
10,133
|
15,386
|
30,445
|
|||||||||||||
Net income (loss)
|
$
|
(177,070
|
)
|
$
|
15,554
|
$
|
(157,693
|
)
|
$
|
47,330
|
|||||||
Earnings (loss) per share:
|
|||||||||||||||||
Basic
|
$
|
(5.32
|
)
|
$
|
0.45
|
$
|
(4.68
|
)
|
$
|
1.39
|
|||||||
Diluted(1)
|
$
|
(5.32
|
)
|
$
|
0.45
|
$
|
(4.68
|
)
|
$
|
1.36
|
|||||||
Weighted average common shares
|
|||||||||||||||||
and equivalents:
|
|||||||||||||||||
Basic
|
33,268
|
34,211
|
33,677
|
34,129
|
|||||||||||||
Diluted (1)
|
33,268
|
34,704
|
33,677
|
34,902
|
|||||||||||||
(1) The assumed exercise of stock-based compensation awards for the three and twelve months ended December 31, 2011 was not considered because the impact would be anti-dilutive.
|
Three Months Ended
|
Twelve Months Ended
|
||||||||
December 31, 2010
|
December 31, 2010
|
||||||||
Revenues excluding CMS settlement (1)
|
$
|
173.0
|
$
|
698.0
|
|||||
Revenues attributable to CMS settlement (2)
|
22.3
|
22.3
|
|||||||
Revenues, GAAP basis
|
$
|
195.3
|
$
|
720.3
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||
December 31, 2011
|
December 31, 2011
|
|||||||||||||
Domestic EPS excluding restructuring and impairment charges (4)
|
$
|
0.31
|
$
|
0.98
|
||||||||||
International EPS (loss) excluding restructuring charges (5)
|
(0.04
|
)
|
(0.13
|
)
|
||||||||||
Adjusted EPS (6)
|
$
|
0.27
|
$
|
0.85
|
||||||||||
EPS (loss) attributable to restructuring charges (7)
|
(0.17
|
)
|
(0.16
|
)
|
||||||||||
EPS (loss) attributable to impairment charges (8)
|
(5.43
|
)
|
(5.36
|
)
|
||||||||||
EPS (loss), GAAP basis (9)
|
$
|
(5.32
|
)
|
$
|
(4.68
|
)
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||
December 31, 2010
|
December 31, 2010
|
|||||||||||||
Domestic EPS excluding restructuring charges, earn-out adjustment and investment gain, and CMS settlement (10)
|
$
|
0.28
|
$
|
1.14
|
||||||||||
International EPS (loss) excluding restructuring charges (11)
|
(0.03
|
)
|
(0.03
|
)
|
||||||||||
Adjusted EPS (12)
|
$
|
0.25
|
$
|
1.11
|
||||||||||
EPS (loss) attributable to restructuring charges (13)
|
(0.20
|
)
|
(0.20
|
)
|
||||||||||
EPS attributable to earn-out adjustment and investment gain (14)
|
0.03
|
0.07
|
||||||||||||
EPS attributable to CMS settlement (15)
|
0.37
|
0.37
|
||||||||||||
EPS, GAAP basis (16)
|
$
|
0.45
|
$
|
1.36
|
December 31,
|
December 31,
|
|||||||||||
2011
|
2010
|
|||||||||||
Current assets:
|
||||||||||||
Cash and cash equivalents
|
$
|
864
|
$
|
1,064
|
||||||||
Accounts receivable, net
|
97,459
|
89,108
|
||||||||||
Prepaid expenses
|
11,417
|
12,577
|
||||||||||
Other current assets
|
1,412
|
3,064
|
||||||||||
Income taxes receivable
|
6,065
|
8,695
|
||||||||||
Deferred tax asset
|
10,314
|
11,272
|
||||||||||
Total current assets
|
127,531
|
125,780
|
||||||||||
Property and equipment:
|
||||||||||||
Leasehold improvements
|
41,622
|
40,662
|
||||||||||
Computer equipment and related software
|
239,732
|
207,077
|
||||||||||
Furniture and office equipment
|
26,324
|
27,328
|
||||||||||
Capital projects in process
|
17,811
|
10,117
|
||||||||||
325,489
|
285,184
|
|||||||||||
Less accumulated depreciation
|
(183,301
|
)
|
(154,528
|
)
|
||||||||
142,188
|
130,656
|
|||||||||||
Other assets
|
10,797
|
14,733
|
||||||||||
Intangible assets, net
|
92,997
|
94,255
|
||||||||||
Goodwill, net
|
335,392
|
496,265
|
||||||||||
Total assets
|
$
|
708,905
|
$
|
861,689
|
||||||||
December 31,
|
December 31,
|
|||||||
2011
|
2010
|
|||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
22,578
|
$
|
22,555
|
||||
Accrued salaries and benefits
|
35,617
|
39,157
|
||||||
Accrued liabilities
|
28,639
|
31,532
|
||||||
Deferred revenue
|
9,273
|
5,931
|
||||||
Contract billings in excess of earned revenue
|
13,154
|
18,814
|
||||||
Current portion of long-term debt
|
3,725
|
3,935
|
||||||
Current portion of long-term liabilities
|
5,771
|
3,309
|
||||||
Total current liabilities
|
118,757
|
125,233
|
||||||
Long-term debt
|
266,117
|
243,425
|
||||||
Long-term deferred tax liability
|
26,964
|
23,050
|
||||||
Other long-term liabilities
|
31,351
|
39,140
|
||||||
Stockholders’ equity:
|
||||||||
Preferred stock
|
||||||||
$.001 par value, 5,000,000 shares
|
||||||||
authorized, none outstanding
|
—
|
—
|
||||||
Common stock
|
||||||||
$.001 par value, 120,000,000 shares authorized,
|
||||||||
33,304,681 and 34,018,706 shares outstanding
|
33
|
34
|
||||||
Additional paid-in capital
|
247,137
|
232,524
|
||||||
Retained earnings
|
48,517
|
206,210
|
||||||
Treasury stock, at cost, 2,254,953 and 429,654 shares in treasury
|
(28,182
|
)
|
(4,494
|
)
|
||||
Accumulated other comprehensive loss
|
(1,789
|
)
|
(3,433
|
)
|
||||
Total stockholders’ equity
|
265,716
|
430,841
|
||||||
Total liabilities and stockholders’ equity
|
$
|
708,905
|
$
|
861,689
|
||||
Twelve Months Ended
|
||||||||||
December 31,
|
||||||||||
2011
|
2010
|
|||||||||
Cash flows from operating activities:
|
||||||||||
Net income (loss)
|
$
|
(157,693
|
)
|
$
|
47,330
|
|||||
Adjustments to reconcile net income to net cash provided by
|
||||||||||
operating activities, net of business acquisitions:
|
||||||||||
Depreciation and amortization
|
49,988
|
52,756
|
||||||||
Impairment loss
|
183,288
|
—
|
||||||||
Amortization of deferred loan costs
|
1,894
|
1,827
|
||||||||
Gain on sale of investment
|
—
|
(1,163
|
)
|
|||||||
Share-based employee compensation expense
|
9,246
|
11,450
|
||||||||
Deferred income taxes
|
(3,572
|
)
|
16,682
|
|||||||
Excess tax benefits from share-based payment arrangements
|
(433
|
)
|
(1,067
|
)
|
||||||
(Increase) decrease in accounts receivable, net
|
(7,452
|
)
|
12,207
|
|||||||
Decrease (increase) in other current assets
|
6,960
|
(159
|
)
|
|||||||
Increase (decrease) in accounts payable
|
1,466
|
(2,256
|
)
|
|||||||
Decrease in accrued salaries and benefits
|
(8,932
|
)
|
(19,715
|
)
|
||||||
Increase (decrease) in other current liabilities
|
2,676
|
(45,206
|
)
|
|||||||
Other
|
(1,144
|
)
|
201
|
|||||||
Net cash flows provided by operating activities
|
76,292
|
72,887
|
||||||||
Cash flows from investing activities:
|
||||||||||
Acquisition of property and equipment
|
(49,290
|
)
|
(44,431
|
)
|
||||||
Sale of investment
|
—
|
1,163
|
||||||||
Business acquisitions, net of cash acquired
|
(23,523
|
)
|
—
|
|||||||
Other
|
(6,889
|
)
|
(5,581
|
)
|
||||||
Net cash flows used in investing activities
|
(79,702
|
)
|
(48,849
|
)
|
||||||
Cash flows from financing activities:
|
||||||||||
Proceeds from issuance of long-term debt
|
439,621
|
656,997
|
||||||||
Payments of long-term debt
|
(417,490
|
)
|
(673,188
|
)
|
||||||
Deferred loan costs
|
—
|
(3,219
|
)
|
|||||||
Excess tax benefits from share-based payment arrangements
|
433
|
1,067
|
||||||||
Exercise of stock options
|
4,825
|
1,133
|
||||||||
Repurchases of common stock
|
(23,688
|
)
|
(4,494
|
)
|
||||||
Change in outstanding checks and other
|
(711
|
)
|
(3,717
|
)
|
||||||
Net cash flows provided by (used in) financing activities
|
2,990
|
(25,421
|
)
|
|||||||
Effect of exchange rate changes on cash
|
220
|
91
|
||||||||
Net decrease in cash and cash equivalents
|
(200
|
)
|
(1,292
|
)
|
||||||
Cash and cash equivalents, beginning of period
|
1,064
|
2,356
|
||||||||
Cash and cash equivalents, end of period
|
$
|
864
|
$
|
1,064
|
Noncash Activities:
|
||||||||||
Assets acquired through capital lease obligations
|
$
|
—
|
$
|
8,435
|
||||||
Issuance of unregistered common stock associated with Navvis acquisition
|
$
|
3,262
|
$
|
—
|
||||||